Co-Diagnostics Advances FDA Submission Amid Mixed Q2 Financials — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Submitted FDA 510(k) application for Co-Dx PCR Flu A/B & RSV test, marking a key regulatory milestone.
Reported Q2 revenue of $0.17M, up slightly from $0.16M in Q2 2025, with operating loss narrowing to $6.2M from $8.1M.
Secured Saudi approval for manufacturing facility and lease agreement in Sudair Industrial City for CoMira Diagnostics.
Expanded Vector Smart® customer footprint to 21 U.S. states with four new mosquito abatement district installations.

The big picture

Co-Diagnostics is positioning itself as a player in the integrated molecular diagnostics space, combining instrumentation, assays, cloud connectivity, and AI. The FDA submission for its Flu A/B & RSV test is a critical step toward commercializing its point-of-care platform. However, the company's ability to sustain financial discipline while expanding globally will be key to long-term success.

What we're watching

Regulatory Approval Timing: Whether the FDA will clear the Co-Dx PCR Flu A/B & RSV test within expected timelines, given the extensive clinical and analytical performance studies completed.
International Expansion Pace: How quickly Co-Diagnostics can scale its manufacturing and commercialization efforts in Saudi Arabia and other international markets.
Financial Sustainability: Whether the company can maintain reduced operating expenses while advancing its regulatory and commercial priorities, given the narrow revenue growth.